Drugs Made In America Acquisition II Corp. cash flow statement DMIIU

In fiscal 2025, which ended Dec 31, 2025, Drugs Made In America Acquisition II Corp. used $1.0 million of cash from operations.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

Line
FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
Operating
Operating cash flow
—
-1
Investing
Investing cash flow
—
-500
Financing
Financing cash flow
—
501
Ratios
Cash conversion
—
-0.24x
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Blank Checks (SIC 6770)
Listed as
DMII (Nasdaq), DMIIR (Nasdaq), DMIIU (Nasdaq)
Fiscal year ends
December 31
Headquarters
New York, NY
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
2040475

Other Blank Checks companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.